PerZeption
PerZeption Inc. is a Boston-based healthcare technology company offering the cloud-based AIM platform for rapid, self-administered visual function testing. It serves ophthalmology practices, clinical trial sponsors, and pediatric vision programs with a suite of 20+ vision tests.
- Company typePrivate
- Founded2021
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What PerZeption does
PerZeption Inc. is a Boston-based, privately held healthcare technology company founded in 2021 that develops the Angular Indication Measurement (AIM) platform, a HIPAA-compliant, cloud-based system for delivering rapid, self-administered visual function tests on tablet and desktop devices. The platform offers a comprehensive suite of over 20 vision tests spanning acuity, contrast sensitivity, color vision, motion, and binocular alignment, using response-adaptive algorithms that personalize test difficulty in real time. Its proprietary AIM+ contrast sensitivity function (CSF) modeling technology is engineered to allow approximately 20 subjects to achieve 90% statistical power to detect a 1 JND change in Area Under the Log Contrast Sensitivity Function in under three minutes, with stable repeatability and no detected bias.
The company serves three primary segments: clinical trial sponsors and research institutions in vision correction, refractive surgery, and amblyopia (where AIM is positioned as a candidate next-generation visual endpoint); ophthalmology practices and eye care providers seeking to reduce clinician chair time by up to 75% through self-administered testing; and pediatric vision assessment programs. PerZeption generates revenue through subscription-based licensing of its cloud platform to healthcare institutions and clinical trial sponsors via a quote-based enterprise model, with pricing not publicly disclosed. The company's go-to-market relies on enterprise field sales, advisor-led relationship building in the ophthalmology industry, and scientific validation channels including peer-reviewed presentations at the ARVO 2026 Annual Meeting, where it collaborated with Alcon Research across five research posters. The platform is grounded in a patent portfolio of 13 inventions held by its co-founders and is supported by a network of academic and clinical partners including Harvard Medical School, Mass Eye and Ear, and Northeastern University.
PerZeption firmographics
Firmographics- Name
- PerZeption
- Legal name
- PerZeption Inc.
- Website
- https://perzeption.vision
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PerZeption Inc. is a Boston-based healthcare technology company offering the cloud-based AIM platform for rapid, self-administered visual function testing. It serves ophthalmology practices, clinical trial sponsors, and pediatric vision programs with a suite of 20+ vision tests.
- Ownership category
- akta.pro rank
PerZeption industry classification
Industry- Product category
- Ophthalmic Diagnostic Software
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)
- akta.pro secondary industry
- Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment) (HLAHAJAM)
Keywords
Where PerZeption is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
PerZeption business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Vision Testing Platform Licensing: PerZeption generates revenue through licensing its cloud-based AIM vision testing platform to healthcare institutions, clinical trial sponsors, and eye care providers. The platform is positioned for use in clinical settings and as a next-generation visual endpoint for clinical trials in vision correction, refractive surgery, and amblyopia.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
PerZeption product offering
Product offeringCore offering
PerZeption develops and licenses a cloud-based, tablet- and computer-accessible Angular Indication Measurement (AIM) platform that delivers self-administered visual function tests covering acuity, contrast sensitivity, color vision, motion, and binocular alignment. The platform uses response-adaptive algorithms to personalize assessments and is positioned for both in-clinic eye care use and as a next-generation visual endpoint for clinical trials in vision correction, refractive surgery, and amblyopia.
Product overview
PerZeption offers a unified cloud-based vision testing platform anchored by its Angular Indication Measurement (AIM) platform, a tablet- and computer-based system delivering over 20 visual function tests (acuity, contrast, color, motion, and binocular alignment). The AIM+ CSF Modeling Technology module extends the core platform with contrast sensitivity function modeling for highly sensitive vision assessment. All products feature response-adaptive testing, cloud-based analytics, and self-administered capabilities designed to reduce clinical chair time by up to 75%.
Differentiator
Problem solved
Functional benefit
Products and services
- Angular Indication Measurement (AIM) Platform Cloud-based, HIPAA-compliant, tablet- and computer-based system delivering fast, repeatable, self-administered visual function tests covering acuity, contrast sensitivity, color vision, motion, and binocular alignment. It uses response-adaptive, personalized testing algorithms to reduce clinician chair time by up to 75% and is licensed to ophthalmology practices, hospital eye departments, and clinical trial sponsors.
Quantifiable outcome
- 90% statistical power to detect a 1 JND change in AULCSF in under 3 minutes with stable repeatability and no detected bias
- +2 more outcomes
Companies that use PerZeption
Customer profileSegments3 records
Ideal customer profiles2 records
PerZeption technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
PerZeption partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- Alcon ResearchcorePerZeption announced a collaboration with Alcon Research to present new data validating its AIM+ CSF modeling technology at the ARVO 2026 annual meeting. Data was presented across five research posters spanning psychophysics, color vision, metacognition, contrast sensitivity, and pediatric binocular vision. This collaboration positions PerZeption as a credible player in the ophthalmology clinical trials ecosystem.
- Mass Eye and EarminorListed as a partner on PerZeption's website. Nature of collaboration not further specified in available materials.
- Harvard Medical SchoolminorListed as a partner on PerZeption's website. Nature of collaboration not further specified in available materials.
- Northeastern UniversitycoreCo-founder Dr. Peter Bex is a Professor of Psychology at Northeastern University with over 25 years of clinical visual neuroscience experience. The university partnership underpins PerZeption's research and development capabilities.
- UC BerkeleyminorListed as a partner on PerZeption's website. Nature of collaboration not further specified in available materials.
- UC IrvineminorListed as a partner on PerZeption's website. Nature of collaboration not further specified in available materials.
- Bilkent UniversityminorListed as a partner on PerZeption's website. Nature of collaboration not further specified in available materials.
- New England College of OptometryminorListed as a partner on PerZeption's website. Nature of collaboration not further specified in available materials.
- University of MichiganminorListed as a partner on PerZeption's website. Nature of collaboration not further specified in available materials.
- University of NevadaminorListed as a partner on PerZeption's website. Nature of collaboration not further specified in available materials.
- University of PlymouthminorListed as a partner on PerZeption's website. Nature of collaboration not further specified in available materials.
- University of TorontominorListed as a partner on PerZeption's website. Nature of collaboration not further specified in available materials.
Scale indicators3 records
Recent moves4 records
Expansion highlights4 records
PerZeption competitors and assessment
Company assessmentDirect peers
- Stereo Optical: Stereo Optical produces the Functional Acuity Contrast Test (FACT) and other standardized contrast sensitivity tests widely used in ophthalmology practices and clinical research. Competes with PerZeption in the contrast sensitivity assessment niche.
- RightEye: RightEye offers cloud-based, automated functional vision and neurological assessments using eye-tracking technology, sold into healthcare and performance markets. Directly comparable to PerZeption's tablet/cloud model for self-administered vision testing.
- Metrovision: Metrovision manufactures computerized perimeters and functional vision testing systems (contrast sensitivity, visual fields) used by eye care professionals. Direct peer offering automated clinical vision assessment comparable to the AIM platform.
- Konan Medical: Konan Medical (formerly VectorVision) manufactures automated clinical vision testing equipment including the CSV-1000HD contrast sensitivity test used in ophthalmology and clinical trials. Directly competes with PerZeption's AIM+ CSF in functional vision assessment.
- Good-Lite: Good-Lite is a long-established manufacturer of clinical vision testing equipment including the CSV-1000 contrast sensitivity test and standardized acuity charts, sold into optometry and ophthalmology practices. Direct peer in functional vision assessment tools.
Others
- Ora Clinical: Ora is a clinical research organization specializing in ophthalmology trials, including development and qualification of novel clinical endpoints. Adjacent peer relevant to PerZeption's positioning of AIM as a next-generation visual trial endpoint.
Broad incumbents
- Carl Zeiss Meditec: Carl Zeiss Meditec is a global medical technology leader with a broad ophthalmology portfolio spanning diagnostic devices, surgical microscopes, and laser systems. Overlaps with PerZeption through ophthalmic diagnostics but competes as part of a much larger, diversified platform.
- Heidelberg Engineering: Heidelberg Engineering is a leading manufacturer of ophthalmic imaging and diagnostic platforms (SPECTRALIS, HRT) widely used in retinal and glaucoma care. Broad incumbent in eye diagnostics, competing via imaging rather than functional vision testing.
- Topcon Healthcare: Topcon Healthcare is a major ophthalmic equipment manufacturer offering diagnostic imaging, refraction, and screening instruments to eye care providers worldwide. Broad incumbent in ophthalmic diagnostics, adjacent to PerZeption's functional vision testing focus.
Emerging players
- Notal Vision: Notal Vision provides home-based, self-administered vision monitoring (ForeseeHome) for patients with retinal disease. Partial overlap with PerZeption's self-administered, cloud-based model, though focused on remote monitoring rather than in-clinic functional assessment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
PerZeption social profiles
Digital presencePerZeption compliance and trust
Trust signalCompliance1 record
PerZeption financial estimates
Financial estimateRevenue estimate
Valuation estimate
PerZeption leadership team
Management profileNumber of profiles
Profiles5 records
PerZeption funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PerZeption M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PerZeption
What does PerZeption do?
PerZeption develops and licenses a cloud-based, tablet- and computer-accessible Angular Indication Measurement (AIM) platform that delivers self-administered visual function tests covering acuity, contrast sensitivity, color vision, motion, and binocular alignment. The platform uses response-adaptive algorithms to personalize assessments and is positioned for both in-clinic eye care use and as a next-generation visual endpoint for clinical trials in vision correction, refractive surgery, and amblyopia.
Is PerZeption a public or private company?
PerZeption is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was PerZeption founded?
PerZeption was founded in 2021. It employs 1 to 10 people.
Where is PerZeption based?
PerZeption is headquartered in Boston, United States, in the North America region.
How does PerZeption make money?
One revenue line is on record: vision Testing Platform Licensing.
Who are PerZeption's main competitors?
Direct peers on record are Stereo Optical, RightEye, Metrovision, Konan Medical and Good-Lite. Ora Clinical is listed as an others. Broad incumbents are Carl Zeiss Meditec, Heidelberg Engineering and Topcon Healthcare. Notal Vision is listed as an emerging player.
Does PerZeption have an API?
No public API is recorded for PerZeption.
What industry is PerZeption in?
PerZeption's product category is Ophthalmic Diagnostic Software. Its primary akta.pro industry code is HLAHAJAC, Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity), with a secondary code of HLAHAJAM, Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment). Its NAICS code is 3345 and its SIC code is 3841.